HER2 Alterations in Non-Small Cell Lung Cancer : Episode 1

Video

September 12, 2022

Biomarker Testing in NSCLC: Clinical Scenario

Author(s):

Solange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Now Viewing

EP: 1.Biomarker Testing in NSCLC: Clinical Scenario

EP: 2.Approaches to Biomarker Testing in NSCLC

EP: 3.Liquid vs Solid Tumor Biopsies in NSCLC

EP: 4.HER2 Alterations in NSCLC: Clinical Scenario

EP: 5.The Role of HER2 Alterations in NSCLC

EP: 6.Testing Patients with NSCLC for HER2 Mutations

EP: 7.Current Treatment Options in NSCLC

EP: 8.Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

EP: 9.HER2-Targeted Therapies in NSCLC

EP: 10.Major Adverse Events of Anti-HER2 Therapies

EP: 11.Unmet Needs in NSCLC Therapy

EP: 12.Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

EP: 13.Novel HER2-Targeted Therapies for NSCLC

Related Content

Lung cancer, Image credit: Axel Kock – stock.adobe.com

November 20th 2024

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

November 19th 2024

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC

October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

November 18th 2024

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10